Evaluating Impact of Empagliflozin on Lipid Profile of Patients of Type 2 Diabetes Mellitus
Abstract
OBJECTIVES:
To assess the effect of two doses, i.e., 10 mg and 25 mg of empagliflozin, on the lipid profile of patients with type 2 diabetes mellitus (T2DM) with suboptimal glycemic control on maximal doses of metformin and sitagliptin.
METHODOLOGY:
The study design was a randomized, open-label clinical trial. Fifty-nine adult patients of T2DM who were already on 2000 mg of Metformin and 100 mg of Sitagliptin and were having suboptimal glycaemic control (HBA1C > 7% <12%) were randomly allocated in 1:1 ratio to two groups, one group receiving 10 mg (Group A) and the other group receiving 25 mg of Empagliflozin (Group B) as an additional treatment. Fasting lipid profiles, including total cholesterol (TC), low-density cholesterol (LDL-C), high-density cholesterol (HDL-C) and triglycerides (TG), were taken before and 12 weeks after the addition of empagliflozin in both the groups.
RESULTS:
Total patients in group A were 31, and their mean age was 51.48±4.29 years. In group B, there were 28 patients, whose mean age was 52.39 ± 5.20 years. There was an increase in TC, LDL-C and HDL-C and a reduction of TG in both the groups after treatment with empagliflozin, but it was not statistically significant (p > 0.05).
CONCLUSION:
Both doses of Empagliflozin (10 and 25 mg) modestly elevates total cholesterol, LDL-C and HDL-C and modestly reduce triglyceride levels in T2DM patients, but the change is not statistically significant.
KEYWORDS: Empagliflozin, Type 2 diabetes mellitus, Total…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 28 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.